Browse the evidence

In integrated primary care weight management, achieving clinically meaningful weight loss (≥5% initial body weight) is significantly associated with higher treatment visit frequency and the simultaneous prescription of two or more anti-obesity medications (AOMs).

To maximize your chances of losing at least 5% of your body weight, commit to attending your scheduled monthly appointments for the first six months and discuss with your doctor the potential benefit of using two anti-obesity medications simultaneously if one isn't working. Consistent engagement and combination therapy were key factors in successful weight loss trajectories in this study.

A history of metabolic surgery (specifically sleeve gastrectomy) significantly attenuates the weight-loss efficacy of liraglutide in patients with mild obesity, resulting in substantially lower total weight loss compared to non-surgical patients.

If you have had weight-loss surgery (especially sleeve gastrectomy), standard doses of liraglutide may not work as well as they do for others. Your doctor might need to increase your dose to 3.0 mg (if approved/available) or switch you to a different medication like tirzepatide to achieve similar weight loss results. Do not assume the standard dose will be sufficient.

Systematic screening for heart failure with preserved ejection fraction (HFpEF) in asymptomatic or mildly symptomatic individuals with obesity is clinically indicated to enable early detection and intervention, as obesity-related HFpEF presents with distinct pathophysiology and earlier onset.

If you have obesity, do not assume shortness of breath or fatigue is 'just part of being overweight.' Ask your doctor about screening for heart failure with preserved ejection fraction (HFpEF), especially if you have other risk factors like high blood pressure or atrial fibrillation. Early detection through specific tests (like echocardiograms or biomarker adjustments) can allow for treatments that prevent heart failure from developing.

Tirzepatide maintenance therapy (either at maximum tolerated dose or reduced to 5 mg) is designed to prevent the weight regain seen with placebo, with rescue protocols available for significant regain.

This paper outlines a trial testing if you can stay on a lower dose of tirzepatide (5mg) or stay on your highest effective dose to keep weight off, compared to stopping it. It also includes a safety net: if you regain more than half your lost weight, you get 'rescue' treatment.

Tirzepatide use is associated with a significantly lower risk of suicidal ideation or suicide attempts compared to other anti-obesity medications in a real-world cohort.

Current real-world evidence suggests that tirzepatide is not associated with an increased risk of suicide and may be associated with a lower risk compared to other anti-obesity medications. However, because this is an observational study, it does not prove causation. Patients with a history of suicidality were excluded, so this data does not apply to high-risk individuals. Consult your provider for personalized psychiatric risk assessment.

GLP-1 receptor agonist therapy for obesity effectively supports weight loss and improves quality of life, but long-term sustainability is undermined by high medication costs, inadequate multidisciplinary support, and significant side effects leading to discontinuation.

GLP-1 medications like Tirzepatide and Semaglutide are effective for weight loss and improving quality of life for many users. However, long-term success is not guaranteed. High costs and side effects are the main reasons people stop treatment. If you are considering or using these medications, be aware that discontinuation often leads to weight regain. Ensure you have a plan for managing costs and side effects, and consider seeking multidisciplinary support (dietary, psychological) to improve adherence and sustainability.

Tirzepatide, a dual GIP/GLP-1 receptor agonist, achieves superior weight loss and hepatic steatosis reduction compared to semaglutide, with preliminary cardiovascular non-inferiority data.

If you have Type 2 Diabetes and fatty liver disease, ask your doctor about Tirzepatide. It is a newer medication that has shown superior weight loss and liver fat reduction compared to other GLP-1 drugs. While cardiovascular outcome data is still being finalized, it is a powerful option for managing both conditions.

Initiating anti-obesity medications more than 12 months after bariatric surgery is associated with a significantly lower risk of adverse events compared to initiation within the first 12 months.

If you are considering weight loss medication after bariatric surgery, current evidence suggests it may be safer to wait until at least 12 months have passed since your surgery. Starting medication earlier is associated with a much higher risk of adverse events, though this may be partly due to the natural recovery period of the surgery itself rather than the drug alone.

Caffeine supplementation, while beneficial for endurance performance, may impair shooting accuracy in biathletes and should be used with caution.

Be cautious with caffeine. While it helps you ski faster, it might make your shooting less accurate. Test it in training to see how it affects your specific shooting performance before using it in competition.

Biathletes should monitor iron and vitamin D levels, as deficiencies are common in endurance sports and can impair performance and health, even if general micronutrient deficiencies are less common in biathletes due to high caloric intake.

Get your iron and vitamin D levels checked regularly. If you are deficient, supplement as directed by your healthcare provider. Focus on iron-rich foods (meat, fish, legumes) and vitamin D sources (sunlight, fortified foods, or supplements if needed).

The menopausal transition is associated with a reduction in lean or muscle mass, with postmenopausal women showing approximately 5.7% lower muscle mass compared to premenopausal women, although this correlation may be confounded by aging and measurement limitations of DXA.

If you are going through menopause, expect a potential decline in muscle mass, particularly during the perimenopausal transition. This is not necessarily inevitable or irreversible. Focus on resistance training and adequate protein intake during this window, as it is a critical period where interventions may be most effective in preventing sarcopenia.

Older women may exhibit elevated fasted muscle protein synthesis (MPS) rates compared to younger women or age-matched men, but their MPS response to anabolic stimuli like resistance exercise or protein ingestion may be blunted.

As you age, your muscles may not respond as strongly to exercise and protein as they did when you were younger. This doesn't mean exercise is useless, but it does mean you may need to be more consistent and potentially adjust your protein intake to maximize muscle protein synthesis.

In 60–65-year-old women, skeletal muscle mass is independently predicted by protein intake per kilogram of body weight, whereas in men of the same age, muscle mass is associated with protein intake and hard leisure-time physical activity, but not other dietary factors.

For seniors aged 60-65, maintaining muscle mass requires sex-specific strategies. Women should focus on adequate protein intake per kg of body weight combined with moderate health-related physical activity, as other nutrients like magnesium and phosphorus also play a role. Men should prioritize total protein intake and engage in harder, vigorous leisure-time physical activity, as other dietary factors do not significantly predict muscle mass in this group.

Vegetarian diets may enhance endurance performance (VO2 max and time to exhaustion) compared to omnivorous diets, likely due to higher carbohydrate availability.

If your primary goal is endurance, a vegan or vegetarian diet may offer a slight advantage in VO2 max and time to exhaustion compared to an omnivorous diet, potentially due to higher carbohydrate intake.

Performing resistance training in the late afternoon/evening yields greater muscle hypertrophy compared to morning training in young, intermediate chronotype males.

If your goal is maximum muscle growth and you are a young adult with a normal schedule, try to schedule your weightlifting sessions for the late afternoon or early evening (e.g., 4 PM - 8 PM). This timing aligns with higher BMAL1 gene expression and body temperature, potentially optimizing muscle synthesis compared to morning sessions.

Performing aerobic exercise in the morning (fasted or pre-breakfast) increases 24-hour fat oxidation compared to exercising in the afternoon or evening.

If your goal is to maximize fat oxidation over the entire day, try doing your cardio before breakfast. However, be aware that this effect might depend on your fasting state; if you eat a meal 3 hours before exercise, this timing benefit may disappear.

Performing resistance training in the morning improves morning performance, while evening training improves evening performance, allowing athletes to optimize for competition times.

If you have a competition at a specific time of day, train at that same time of day for several weeks. This will shift your peak performance to match your event time, improving your results.

Higher self-reported protein and energy intake is significantly associated with greater appendicular lean mass (ALM) in older adults performing resistance training, whereas muscle strength (handgrip) is not associated with nutritional intake.

If you are an older adult doing resistance training, ensure you are eating enough protein and total energy. This study shows that higher intake correlates with higher muscle mass, even in people who are already exercising. Don't rely on exercise alone; nutrition is a key lever for maintaining muscle.

Higher self-reported physical activity (PASE score) is associated with faster gait speed (GS) in older adults, regardless of the type of gym equipment used.

Keep moving outside of your gym sessions. This study shows that older adults who report higher general physical activity tend to walk faster, even if they are already doing resistance training. Don't let gym time replace daily walking.

High protein intake (>236 g/day or >3.30 g/kg/day) combined with long-term supplementation (>1 year) significantly decreases glomerular filtration rate (GFR) and increases serum creatinine in CrossFit athletes compared to adequate intake without supplementation.

If you are a CrossFit athlete consuming more than 3.30 g of protein per kg of body weight daily, especially using supplements for over a year, monitor your kidney function (GFR and creatinine) regularly. High doses over long periods may reduce kidney filtration efficiency, even in healthy athletes.

Training to concentric muscle failure provides greater hypertrophy benefits than non-failure training only when using low-load resistance training; in high-load training, volume-equated failure training offers no significant hypertrophy advantage over non-failure training.

If you are lifting heavy weights (high intensity), you do not need to train to failure to maximize muscle growth; stopping a few reps short is likely equivalent if total volume is matched. However, if you are lifting lighter weights (low intensity), training to failure is likely necessary to stimulate growth comparable to heavy lifting. Adjust your proximity to failure based on your load.

Support Vector Regression (SVR) machine learning models can accurately predict weight loss, fasting blood glucose, and HbA1c outcomes in Type 2 diabetic patients treated with Exenatide, enabling optimized nursing care and treatment decisions.

For nurses managing diabetic patients on Exenatide, using validated machine learning models (specifically SVR) can significantly improve the accuracy of predicting weight loss and glycemic control (HbA1c/Fasting Glucose). This allows for proactive adjustments to nursing care plans, dietary advice, and lifestyle interventions before complications arise, rather than reacting to poor outcomes after they occur.

Regular meal patterns and larger, less frequent meals maximize the Thermic Effect of Food (TEF) compared to irregular or frequent small meals.

Try eating fewer, larger meals rather than grazing throughout the day. Regular, larger meals may trigger a higher thermic effect of food (more calories burned during digestion) and help manage hunger signals better than frequent small snacks.

Garcinia cambogia (Hydroxycitric acid/HCA) supplementation reduces visceral fat and improves fasting blood glucose and insulin sensitivity in overweight/obese individuals.

Garcinia cambogia (HCA) at 1,000 mg/day may help reduce visceral fat and improve blood sugar in overweight people, but it is not a magic bullet. It works by blocking fat synthesis and suppressing appetite.